{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:49:16Z","timestamp":1791463756653,"version":"4.3.4"},"reference-count":159,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z171100000417007"],"award-info":[{"award-number":["Z171100000417007"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["Z181100006218044"],"award-info":[{"award-number":["Z181100006218044"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31530020"],"award-info":[{"award-number":["31530020"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971523"],"award-info":[{"award-number":["81971523"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["2101000537"],"award-info":[{"award-number":["2101000537"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81671604"],"award-info":[{"award-number":["81671604"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81302554"],"award-info":[{"award-number":["81302554"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["PKU2019LCXQ018"],"award-info":[{"award-number":["PKU2019LCXQ018"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007937","name":"Peking University","doi-asserted-by":"publisher","award":["RDF2019-03"],"award-info":[{"award-number":["RDF2019-03"]}],"id":[{"id":"10.13039\/501100007937","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.jaut.2020.102504","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T14:06:25Z","timestamp":1592661985000},"page":"102504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["LAG3 (CD223) and autoimmunity: Emerging evidence"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5368-1354","authenticated-orcid":false,"given":"Suiyuan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianding","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanguo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanlei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2020.102504_bib1","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3389\/fimmu.2018.01909","article-title":"Not all immune checkpoints are created equal","volume":"9","author":"De Sousa Linhares","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","article-title":"Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4","volume":"18","author":"Qin","year":"2019","journal-title":"Mol. Canc."},{"issue":"Suppl 1","key":"10.1016\/j.jaut.2020.102504_bib4","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1038\/gene.2009.88","article-title":"Remapping the type I diabetes association of the CTLA4 locus","volume":"10","author":"Qu","year":"2009","journal-title":"Gene Immun."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1615\/CritRevImmunol.v31.i4.10","article-title":"PD-1 and autoimmunity","volume":"31","author":"Kasagi","year":"2011","journal-title":"Crit. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib6","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jaut.2020.102504_bib7","first-page":"269","article-title":"LAG-3 in cancer immunotherapy","volume":"344","author":"Goldberg","year":"2011","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.jaut.2020.102504_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu. Rev. Immunol."},{"issue":"26","key":"10.1016\/j.jaut.2020.102504_bib9","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"6382","key":"10.1016\/j.jaut.2020.102504_bib10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6165","key":"10.1016\/j.jaut.2020.102504_bib11","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib12","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib13","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib14","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102504_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aay4458","article-title":"Molecular mechanism of SHP2 activation by PD-1 stimulation","volume":"6","author":"Marasco","year":"2020","journal-title":"Sci. Adv."},{"issue":"19","key":"10.1016\/j.jaut.2020.102504_bib16","doi-asserted-by":"crossref","first-page":"12293","DOI":"10.1073\/pnas.192461099","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","volume":"99","author":"Iwai","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"25","key":"10.1016\/j.jaut.2020.102504_bib17","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102504_bib18","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.4049\/jimmunol.172.9.5450","article-title":"Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo","volume":"172","author":"Workman","year":"2004","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib20","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.4049\/jimmunol.169.10.5392","article-title":"Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3","volume":"169","author":"Workman","year":"2002","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jaut.2020.102504_bib22","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fimmu.2018.00385","article-title":"Targeting LAG-3 and PD-1 to enhance T cell activation by antigen-presenting cells","volume":"9","author":"Lichtenegger","year":"2018","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.immuni.2018.12.024","article-title":"Liver-resident NK cells control antiviral activity of hepatic T cells via the PD-1-PD-L1 Axis","volume":"50","author":"Zhou","year":"2019","journal-title":"Immunity"},{"issue":"1\u20132","key":"10.1016\/j.jaut.2020.102504_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jaut.2020.102504_bib25","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib26","first-page":"503","article-title":"Role of LAG-3 in regulatory T cells, immunity","volume":"21","author":"Huang","year":"2004"},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib27","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1002\/eji.200526090","article-title":"Expression of lymphocyte activation gene 3 (LAG-3) on B cells is induced by T cells,","volume":"35","author":"Kisielow","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.immuni.2018.06.007","article-title":"LAG-3 inhibitory receptor expression identifies immunosuppressive natural regulatory plasma cells","volume":"49","author":"Lino","year":"2018","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib29","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.4049\/jimmunol.0800185","article-title":"LAG-3 regulates plasmacytoid dendritic cell homeostasis","volume":"182","author":"Workman","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib30","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1002\/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A","article-title":"Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3)","volume":"32","author":"Workman","year":"2002","journal-title":"Eur. J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib31","doi-asserted-by":"crossref","first-page":"6806","DOI":"10.4049\/jimmunol.173.11.6806","article-title":"Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223)","volume":"173","author":"Li","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib32","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/eji.200323382","article-title":"The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells","volume":"33","author":"Workman","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib33","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1002\/1521-4141(2001010)31:10<2885::AID-IMMU2885>3.0.CO;2-2","article-title":"LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3\/TCR activation pathway","volume":"31","author":"Iouzalen","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/sj.emboj.7601520","article-title":"Metalloproteases regulate T-cell proliferation and effector function via LAG-3","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J."},{"issue":"6","key":"10.1016\/j.jaut.2020.102504_bib35","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/eji.200939874","article-title":"Differential subcellular localization of the regulatory T-cell protein LAG-3 and the coreceptor CD4","volume":"40","author":"Woo","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.jaut.2020.102504_bib36","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.4049\/jimmunol.1401025","article-title":"Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling","volume":"193","author":"Bae","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.jaut.2020.102504_bib37","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.4049\/jimmunol.162.5.2748","article-title":"Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells","volume":"162","author":"Avice","year":"1999","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib38","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.canlet.2005.04.015","article-title":"A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors","volume":"235","author":"Triebel","year":"2006","journal-title":"Canc. Lett."},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib39","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.2337\/db11-1591","article-title":"Modulation of redox balance leaves murine diabetogenic TH1 T cells \"LAG-3-ing\" behind","volume":"61","author":"Delmastro","year":"2012","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib40","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1084\/jem.176.2.327","article-title":"Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens","volume":"176","author":"Baixeras","year":"1992","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib41","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1073\/pnas.94.11.5744","article-title":"Characterization of the major histocompatibility complex class II binding site on LAG-3 protein","volume":"94","author":"Huard","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib42","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: an open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib43","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Canc. Immunol. Res."},{"issue":"18","key":"10.1016\/j.jaut.2020.102504_bib44","doi-asserted-by":"crossref","first-page":"18748","DOI":"10.1074\/jbc.M311227200","article-title":"Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and expression in sinusoidal endothelial cells of liver and lymph node","volume":"279","author":"Liu","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"13","key":"10.1016\/j.jaut.2020.102504_bib45","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Canc. Res."},{"issue":"6307","key":"10.1016\/j.jaut.2020.102504_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/science.aah3374","article-title":"Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3","volume":"353","author":"Mao","year":"2016","journal-title":"Science"},{"issue":"6127","key":"10.1016\/j.jaut.2020.102504_bib47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jaut.2020.102504_bib48","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib49","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4049\/jimmunol.156.11.4154","article-title":"Regulation of CTLA-4 expression during T cell activation","volume":"156","author":"Perkins","year":"1996","journal-title":"J. Immunol."},{"issue":"6828","key":"10.1016\/j.jaut.2020.102504_bib50","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"issue":"5609","key":"10.1016\/j.jaut.2020.102504_bib51","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1126\/science.1079490","article-title":"Control of regulatory T cell development by the transcription factor Foxp3","volume":"299","author":"Hori","year":"2003","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.jaut.2020.102504_bib52","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.jaut.2020.102504_bib53","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"17","key":"10.1016\/j.jaut.2020.102504_bib54","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"Cheng","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell. Immunol."},{"issue":"7655","key":"10.1016\/j.jaut.2020.102504_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"6332","key":"10.1016\/j.jaut.2020.102504_bib57","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1126\/science.aaf0683","article-title":"Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent","volume":"355","author":"Kamphorst","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.jaut.2020.102504_bib58","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib59","first-page":"265","article-title":"Biochemical signaling of PD-1 on T cells and its functional implications","volume":"20","author":"Boussiotis","year":"2014","journal-title":"Canc. J."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib60","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/eji.200839116","article-title":"A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC","volume":"39","author":"Boles","year":"2009","journal-title":"Eur. J. Immunol."},{"issue":"42","key":"10.1016\/j.jaut.2020.102504_bib61","doi-asserted-by":"crossref","first-page":"17858","DOI":"10.1073\/pnas.0903474106","article-title":"The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity","volume":"106","author":"Stanietsky","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/ni.1674","article-title":"The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells","volume":"10","author":"Yu","year":"2009","journal-title":"Nat. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib63","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1172\/JCI81187","article-title":"TIGIT predominantly regulates the immune response via regulatory T cells","volume":"125","author":"Kurtulus","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005349","article-title":"TIGIT marks exhausted T cells, correlates with disease progression, and serves as a target for immune restoration in HIV and SIV infection","volume":"12","author":"Chew","year":"2016","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib65","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"issue":"6871","key":"10.1016\/j.jaut.2020.102504_bib66","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/415536a","article-title":"Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease","volume":"415","author":"Monney","year":"2002","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib67","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/ni988","article-title":"Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance","volume":"4","author":"Sabatos","year":"2003","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib68","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.4049\/jimmunol.0903275","article-title":"Tim-3\/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b+Ly-6G+ myeloid cells","volume":"185","author":"Dardalhon","year":"2010","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib69","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J. Exp. Med."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib70","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J. Exp. Med."},{"issue":"1\u20133","key":"10.1016\/j.jaut.2020.102504_bib71","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12026-014-8524-1","article-title":"Regulation of T cell responses by the receptor molecule Tim-3","volume":"59","author":"Gorman","year":"2014","journal-title":"Immunol. Res."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/imr.12520","article-title":"Tim-3 and its role in regulating anti-tumor immunity","volume":"276","author":"Das","year":"2017","journal-title":"Immunol. Rev."},{"issue":"6","key":"10.1016\/j.jaut.2020.102504_bib73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2326-6066.CIR-14-0072","article-title":"VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy","volume":"2","author":"Lines","year":"2014","journal-title":"Canc. Immunol. Res."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib74","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imm.13001","article-title":"VSIG-3 as a ligand of VISTA inhibits human T-cell function","volume":"156","author":"Wang","year":"2019","journal-title":"Immunology"},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/85339","article-title":"B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production","volume":"2","author":"Chapoval","year":"2001","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102504_bib76","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ni967","article-title":"The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses","volume":"4","author":"Suh","year":"2003","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib77","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.4049\/jimmunol.173.4.2500","article-title":"Murine B7-H3 is a negative regulator of T cells","volume":"173","author":"Prasad","year":"2004","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib78","first-page":"66","article-title":"B7-H3 role in the immune landscape of cancer","volume":"6","author":"Castellanos","year":"2017","journal-title":"Afr. J. Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib79","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/imr.12521","article-title":"The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3","volume":"276","author":"Janakiram","year":"2017","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib80","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.bbrc.2003.11.070","article-title":"Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2","volume":"312","author":"Gavrieli","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib81","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.4049\/jimmunol.172.10.5931","article-title":"An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection","volume":"172","author":"Han","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib82","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/ni1144","article-title":"B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator","volume":"6","author":"Sedy","year":"2005","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib83","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1600-065X.2011.01064.x","article-title":"The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation","volume":"244","author":"Steinberg","year":"2011","journal-title":"Immunol. Rev."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib84","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.it.2013.07.003","article-title":"B7 family checkpoint regulators in immune regulation and disease","volume":"34","author":"Ceeraz","year":"2013","journal-title":"Trends Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib85","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41423-019-0241-1","article-title":"HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT","volume":"16","author":"Rodriguez-Barbosa","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.jaut.2020.102504_bib86","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3389\/fimmu.2019.00617","article-title":"BTLA\/HVEM signaling: milestones in Research and role in chronic hepatitis B virus infection","volume":"10","author":"Yu","year":"2019","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib87","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/intimm\/11.11.1745","article-title":"The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3\u2013TCR molecules after their engagement by mAb or peptide\u2013MHC class I complexes","volume":"11","author":"Hannier","year":"1999","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib88","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2567.2005.02145.x","article-title":"The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells","volume":"115","author":"Macon-Lemaitre","year":"2005","journal-title":"Immunology"},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib89","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.4049\/jimmunol.161.8.4058","article-title":"CD3\/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3\/TCR signaling","volume":"161","author":"Hannier","year":"1998","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102504_bib90","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.4049\/jimmunol.180.9.5916","article-title":"Regulatory T cells inhibit dendritic cells by lymphocyte activation gene-3 engagement of MHC class II","volume":"180","author":"Liang","year":"2008","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib91","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.4049\/jimmunol.168.8.3874","article-title":"Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223)","volume":"168","author":"Andreae","year":"2002","journal-title":"J. Immunol."},{"issue":"9\u201310","key":"10.1016\/j.jaut.2020.102504_bib92","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S0264-410X(02)00533-9","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) leads to a distinct pattern of chemokine and chemokine receptor expression by human dendritic cells","volume":"21","author":"Buisson","year":"2003","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.jaut.2020.102504_bib93","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1002\/eji.1830241246","article-title":"Lymphocyte-activation gene 3\/major histocompatibility complex class II interaction modulates the antigenic response of CD4+ T lymphocytes","volume":"24","author":"Huard","year":"1994","journal-title":"Eur. J. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib94","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","article-title":"Molecular signature of CD8+ T cell exhaustion during chronic viral infection","volume":"27","author":"Wherry","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib95","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4049\/jimmunol.1401594","article-title":"LAG-3 confers a competitive disadvantage upon antiviral CD8+ T cell responses","volume":"197","author":"Cook","year":"2016","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib96","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.4049\/jimmunol.0804211","article-title":"Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells","volume":"182","author":"Grosso","year":"2009","journal-title":"J. Immunol."},{"issue":"33","key":"10.1016\/j.jaut.2020.102504_bib97","doi-asserted-by":"crossref","first-page":"13974","DOI":"10.1073\/pnas.0906872106","article-title":"CD4+CD25-LAG3+ regulatory T cells controlled by the transcription factor Egr-2","volume":"106","author":"Okamura","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib98","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","article-title":"Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease","volume":"32","author":"Iyer","year":"2012","journal-title":"Crit. Rev. Immunol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102504_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aah4569","article-title":"LAG3 limits regulatory T cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci. Immunol."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib100","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1089\/dna.2017.3771","article-title":"Overexpression of lymphocyte activation gene-3 inhibits regulatory T cell responses in osteoarthritis","volume":"36","author":"Xia","year":"2017","journal-title":"DNA Cell Biol."},{"issue":"5260","key":"10.1016\/j.jaut.2020.102504_bib101","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1126\/science.272.5260.405","article-title":"Independent modes of natural killing distinguished in mice lacking Lag3","volume":"272","author":"Miyazaki","year":"1996","journal-title":"Science"},{"issue":"2\u20133","key":"10.1016\/j.jaut.2020.102504_bib102","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0165-2478(97)00170-3","article-title":"LAG-3 does not define a specific mode of natural killing in human","volume":"61","author":"Huard","year":"1998","journal-title":"Immunol. Lett."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib103","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cellbi.2006.11.002","article-title":"Proliferation of activated CD1d-restricted NKT cells is down-modulated by lymphocyte activation gene-3 signaling via cell cycle arrest in S phase","volume":"31","author":"Byun","year":"2007","journal-title":"Cell Biol. Int."},{"key":"10.1016\/j.jaut.2020.102504_bib104","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-015-0142-z","article-title":"Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment","volume":"12","author":"Juno","year":"2015","journal-title":"Retrovirology"},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib105","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.4049\/jimmunol.1100714","article-title":"Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3","volume":"187","author":"Bettini","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib106","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.immuni.2018.07.007","article-title":"LAG3(+) regulatory T cells restrain interleukin-23-producing CX3CR1(+) gut-resident macrophages during group 3 innate lymphoid cell-driven colitis","volume":"49","author":"Bauche","year":"2018","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib107","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13075-017-1309-x","article-title":"Interleukin-10-producing LAG3(+) regulatory T cells are associated with disease activity and abatacept treatment in rheumatoid arthritis","volume":"19","author":"Nakachi","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jaut.2020.102504_bib108","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jaut.2016.02.002","article-title":"Lymphocyte-activation gene 3(+) (LAG3(+)) forkhead box protein 3(-) (FOXP3(-)) regulatory T cells induced by B cells alleviates joint inflammation in collagen-induced arthritis","volume":"68","author":"Chen","year":"2016","journal-title":"J. Autoimmun."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/sj.gene.6364171","article-title":"Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis","volume":"6","author":"Zhang","year":"2005","journal-title":"Gene Immun."},{"issue":"1\u20132","key":"10.1016\/j.jaut.2020.102504_bib110","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jneuroim.2006.08.009","article-title":"Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations","volume":"180","author":"Lundmark","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"12","key":"10.1016\/j.jaut.2020.102504_bib111","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1016\/j.jid.2018.05.021","article-title":"Proportion of CD4(+)CD49b(+)LAG-3(+) type 1 regulatory T cells in the blood of psoriasis patients inversely correlates with psoriasis area and severity index","volume":"138","author":"Kim","year":"2018","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2249.2011.04329.x","article-title":"Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates","volume":"164","author":"Poirier","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib113","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Canc. Res."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib114","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104484","article-title":"Lymphocyte Activation Gene-3 (LAG-3) negatively regulates environmentally-induced autoimmunity","volume":"9","author":"Jha","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.jaut.2020.102504_bib115","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib116","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.ajpath.2014.11.003","article-title":"LAG3 expression in active Mycobacterium tuberculosis infections","volume":"185","author":"Phillips","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"9","key":"10.1016\/j.jaut.2020.102504_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0180413","article-title":"LAG-3 potentiates the survival of Mycobacterium tuberculosis in host phagocytes by modulating mitochondrial signaling in an in-vitro granuloma model","volume":"12","author":"Phillips","year":"2017","journal-title":"PloS One"},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib118","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/1348-0421.12354","article-title":"Expression of PD-1\/LAG-3 and cytokine production by CD4(+) T cells during infection with Plasmodium parasites","volume":"60","author":"Doe","year":"2016","journal-title":"Microbiol. Immunol."},{"issue":"2","key":"10.1016\/j.jaut.2020.102504_bib119","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/ni.2180","article-title":"Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection","volume":"13","author":"Butler","year":"2011","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12865-019-0309-9","article-title":"CD4(+) T cell exhaustion revealed by high PD-1 and LAG-3 expression and the loss of helper T cell function in chronic hepatitis B","volume":"20","author":"Dong","year":"2019","journal-title":"BMC Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib121","article-title":"Increasing LAG-3 expression suppresses T-cell function in chronic hepatitis B: a balance between immunity strength and liver injury extent","volume":"96","author":"Ye","year":"2017","journal-title":"Medicine (Baltim.)"},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib122","first-page":"532","article-title":"[Elevated expression of lymphocyte activation gene-3 on peripheral blood CD8(+) T lymphocytes in patients with chronic hepatitis B virus infection]","volume":"32","author":"Ma","year":"2016"},{"key":"10.1016\/j.jaut.2020.102504_bib123","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.imlet.2019.06.003","article-title":"Elevated LAG-3 on CD4(+) T cells negatively correlates with neutralizing antibody response during HCV infection","volume":"212","author":"Zhang","year":"2019","journal-title":"Immunol. Lett."},{"issue":"12","key":"10.1016\/j.jaut.2020.102504_bib124","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/jgh.13017","article-title":"Lymphocyte activation gene 3 negatively regulates the function of intrahepatic hepatitis C virus-specific CD8+ T cells","volume":"30","author":"Chen","year":"2015","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib125","doi-asserted-by":"crossref","first-page":"3873","DOI":"10.4049\/jimmunol.1402176","article-title":"The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects","volume":"194","author":"Tian","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.jaut.2020.102504_bib126","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005761","article-title":"CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART","volume":"12","author":"Fromentin","year":"2016","journal-title":"PLoS Pathog."},{"issue":"10","key":"10.1016\/j.jaut.2020.102504_bib127","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206256","article-title":"Cardiac morbidity in HIV infection is associated with checkpoint inhibitor LAG-3 on CD4 T cells","volume":"13","author":"Pallikkuth","year":"2018","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/intimm\/dxp107","article-title":"On the role of the inhibitory receptor LAG-3 in acute and chronic LCMV infection","volume":"22","author":"Richter","year":"2010","journal-title":"Int. Immunol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/ni.1679","article-title":"Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection","volume":"10","author":"Blackburn","year":"2009","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jaut.2020.102504_bib130","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3389\/fimmu.2018.02922","article-title":"Blockade of LAG-3 immune checkpoint combined with therapeutic vaccination restore the function of tissue-resident anti-viral CD8(+) T cells and protect against recurrent ocular herpes simplex infection and disease","volume":"9","author":"Roy","year":"2018","journal-title":"Front. Immunol."},{"issue":"18","key":"10.1016\/j.jaut.2020.102504_bib131","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00827-19","article-title":"Blockade of PD-1 and LAG-3 immune checkpoints combined with vaccination restores the function of antiviral tissue-resident CD8(+) TRM cells and reduces ocular herpes simplex infection and disease in HLA transgenic rabbits","volume":"93","author":"Roy","year":"2019","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib132","doi-asserted-by":"crossref","first-page":"14600","DOI":"10.1038\/s41598-018-32712-8","article-title":"Lymphocyte activation gene 3 (Lag3) expression is increased in prion infections but does not modify disease progression","volume":"8","author":"Liu","year":"2018","journal-title":"Sci. Rep."},{"issue":"17","key":"10.1016\/j.jaut.2020.102504_bib133","doi-asserted-by":"crossref","first-page":"7875","DOI":"10.1073\/pnas.1003345107","article-title":"Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer","volume":"107","author":"Matsuzaki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.jaut.2020.102504_bib134","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1172\/JCI46102","article-title":"Exhaustion of tumor-specific CD8(+) T cells in metastases from melanoma patients","volume":"121","author":"Baitsch","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib135","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12032-014-0082-9","article-title":"The effect of immune microenvironment on the progression and prognosis of colorectal cancer","volume":"31","author":"Chen","year":"2014","journal-title":"Med. Oncol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib136","doi-asserted-by":"crossref","first-page":"6545","DOI":"10.4049\/jimmunol.0903879","article-title":"LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites","volume":"184","author":"Camisaschi","year":"2010","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.jaut.2020.102504_bib137","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI31184","article-title":"LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems","volume":"117","author":"Grosso","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib138","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/2159-8290.CD-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Canc. Discov."},{"issue":"8","key":"10.1016\/j.jaut.2020.102504_bib139","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/2159-8290.CD-15-1545","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","journal-title":"Canc. Discov."},{"issue":"4","key":"10.1016\/j.jaut.2020.102504_bib140","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"Supplement_1","key":"10.1016\/j.jaut.2020.102504_bib141","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1093\/ecco-jcc\/jjy222.574","article-title":"P450 Association of Infliximab trough levels and transmural healing in Crohn's disease","volume":"13","author":"Bernardo","year":"2019","journal-title":"J. Crohn's and Colitis"},{"issue":"1","key":"10.1016\/j.jaut.2020.102504_bib142","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14712598.2011.540563","article-title":"The CD4-like molecule LAG-3, biology and therapeutic applications","volume":"15","author":"Sierro","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.jaut.2020.102504_bib143","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-8518-5-5","article-title":"IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study","volume":"5","author":"Brignone","year":"2007","journal-title":"J. Immune Base Ther. Vaccine"},{"issue":"24","key":"10.1016\/j.jaut.2020.102504_bib144","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1016\/j.vaccine.2007.04.019","article-title":"IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: a single-blind phase I study","volume":"25","author":"Brignone","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jaut.2020.102504_bib145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1479-5876-8-71","article-title":"First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity","volume":"8","author":"Brignone","year":"2010","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.jaut.2020.102504_bib146","series-title":"Poster O28: Results from a Phase I Dose Escalation Trial (TACTI-Mel) with the Soluble LAG-3 Protein (IMP321, Eftilagimod Alpha) Together with Pembrolizumab in Unresectable or Metastatic Melanoma","author":"Triebel","year":"2018"},{"issue":"6","key":"10.1016\/j.jaut.2020.102504_bib147","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/1078-0432.CCR-15-1212","article-title":"Vaccination with LAG-3ig (IMP321) and peptides induces specific CD4 and CD8 T-cell responses in metastatic melanoma patients--report of a phase I\/IIa clinical trial","volume":"22","author":"Legat","year":"2016","journal-title":"Clin. Canc. Res."},{"issue":"19","key":"10.1016\/j.jaut.2020.102504_bib148","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1158\/1078-0432.CCR-09-0068","article-title":"A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma","volume":"15","author":"Brignone","year":"2009","journal-title":"Clin. Canc. Res."},{"key":"10.1016\/j.jaut.2020.102504_bib149","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1479-5876-12-97","article-title":"MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial","volume":"12","author":"Romano","year":"2014","journal-title":"J. Transl. Med."},{"issue":"15_suppl","key":"10.1016\/j.jaut.2020.102504_bib150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","article-title":"Initial efficacy of anti-lymphocyte activation gene-3 (anti\u2013LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti\u2013PD-1\/PD-L1 therapy","volume":"35","author":"Ascierto","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.jaut.2020.102504_bib151","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS2616","article-title":"A phase 2, open-label study of the combination of spartalizumab (PDR001) and LAG525 for patients with advanced solid tumors and hematologic malignancies","volume":"36","author":"Piha-Paul","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"13 Supplement","key":"10.1016\/j.jaut.2020.102504_bib152","article-title":"Abstract CT106: anti-LAG-3 antibody MK-4280 in combination with pembrolizumab for the treatment of hematologic malignancies: a Phase I\/II study","volume":"79","author":"Gregory","year":"2019","journal-title":"Canc. Res."},{"key":"10.1016\/j.jaut.2020.102504_bib153","series-title":"Abstract O26: the Anti\u2013LAG-3 Antibody MK-4280 as Monotherapy and in Combination with Pembrolizumab for Advanced Solid Tumors: First-In-Human Phase 1 Dose-Finding Study","author":"Lakhani","year":"2018"},{"issue":"15_suppl","key":"10.1016\/j.jaut.2020.102504_bib154","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS3127","article-title":"A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers","volume":"36","author":"Papadopoulos","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jaut.2020.102504_bib155","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/1535-7163.MCT-18-0836","article-title":"TSR-033, a novel therapeutic antibody targeting LAG-3, enhances T-cell function and the activity of PD-1 blockade in vitro and in vivo","volume":"18","author":"Ghosh","year":"2019","journal-title":"Mol. Canc. Therapeut."},{"issue":"13 Supplement","key":"10.1016\/j.jaut.2020.102504_bib156","article-title":"Abstract 5626: preclinical characterization of Sym022, a novel anti-LAG3 antibody","volume":"78","author":"Grandal","year":"2018","journal-title":"Canc. Res."},{"issue":"13 Supplement","key":"10.1016\/j.jaut.2020.102504_bib157","article-title":"Abstract 3819: INCAGN02385 is an antagonist antibody targeting the co-inhibitory receptor LAG-3 for the treatment of human malignancies","volume":"78","author":"Savitsky","year":"2018","journal-title":"Canc. Res."},{"issue":"14 Supplement","key":"10.1016\/j.jaut.2020.102504_bib158","article-title":"Abstract 3217: MGD013, a bispecific PD-1 x LAG-3 Dual-Affinity Re-Targeting (DART\u00ae) protein with T-cell immunomodulatory activity for cancer treatment","volume":"76","author":"LaMotte-Mohs","year":"2016","journal-title":"Canc. Res."},{"issue":"13 Supplement","key":"10.1016\/j.jaut.2020.102504_bib159","article-title":"Abstract 2719: dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+ T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses","volume":"78","author":"Kraman","year":"2018","journal-title":"Canc. Res."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301268?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841120301268?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T19:33:04Z","timestamp":1778700784000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841120301268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":159,"alternative-id":["S0896841120301268"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102504","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"LAG3 (CD223) and autoimmunity: Emerging evidence","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2020.102504","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102504"}}